Legal status · Record reviewed
Tesamorelin has no single legal status. It depends on the product and how it is supplied.
FDA has approved Egrifta SV and Egrifta WR for set uses. The approval covers only those products, not every product sold under the name Tesamorelin.
Sports: the anti-doping rules we checked list it as prohibited (checked August 1, 2026).
Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
Whether you may buy, sell, or use a product also depends on pharmacy (compounding) rules, a prescription, and state law. Read how U.S. peptide law works.
Have a product in hand? Check if it is a prescription, compounded, or research-only product.
FDA-approved product
FDA approved one or more named products for set uses. The approval covers those products only, not every product sold under the same name.
What the record says: An FDA-approved product exists for a narrow indication
Not named on this FDA page
This FDA page does not name it. That does not show that a pharmacy may compound it. Other FDA lists and conditions still apply.
Source: FDA's page of bulk drug substances that may present significant safety risks. FDA marks it current as of . We checked it on .
Prohibited
Tesamorelin is named as a prohibited growth-hormone-releasing hormone analogue on the 2026 WADA Prohibited List and is prohibited at all times for covered athletes.
Checked . Read the rule we checked. Check the current World Anti-Doping Agency list and your sport's rules before you compete.
Other names in this record: Egrifta SV, Egrifta WR, TH9507, GHRF analogue.
What it is, what studies in people show, and what is still unknown.
Open the Tesamorelin recordSee the FDA, compounding, and sports status of every peptide we reviewed in one table.
See all 34 peptides